Key result
Serious ventricular arrhythmia history in adolescent HCM is linked to ~2-fold higher circulating MMP3 levels.
Why the study?
Are circulating matrix metalloproteinases associated with a history of serious ventricular arrhythmia in adolescents with hypertrophic cardiomyopathy?
Observational (n=45)
Are circulating matrix metalloproteinases associated with a history of serious ventricular arrhythmia in adolescents with hypertrophic cardiomyopathy?
Effect estimate: standardized β 0.37
Absolute Event Rate: 12.9% vs 5.8%
p-value: p=0.01
Circulating MMP3 may serve as a biomarker for ventricular arrhythmia risk in adolescent patients with hypertrophic cardiomyopathy, though age-related confounding remains a limitation.
MMP3 may mark arrhythmia risk in adolescent HCM; hypothesis-generating and requires prospective validation before clinical use.
No takes yet. Share an insight, caveat, or question.
Zachariah et al. (2012) conducted an observational in Hypertrophic cardiomyopathy and ventricular arrhythmia (n=45). History of serious ventricular arrhythmia vs. No history of serious ventricular arrhythmia was evaluated on Circulating MMP3 concentration (standardized β 0.37, p=0.01). A history of serious ventricular arrhythmia in adolescents with hypertrophic cardiomyopathy was associated with higher circulating MMP3 concentrations (median 12.9 vs 5.8 μg/mL; P=0.01).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: